A Year in Review: Advancing Patient-Specific Insulin Dosing for Better Outcomes

CEO Quarterly Update

As we close out the year 2024, I’d like to take a moment to reflect on the strides we’ve made in the patient-specific insulin dosing space. Our team has remained steadfast in our mission to improve the lives of nurses, clinicians, and, most importantly, patients who require insulin in inpatient settings. Throughout this year, we have gathered compelling evidence that affirms our commitment to delivering tangible benefits for both providers and patients alike.

This quarter, we hosted a highly popular webinar titled “Why Every Health System Should Use Patient-Specific Insulin Dosing Software.” The panel, comprised of healthcare leaders from some of the nation’s top healthcare institutions, shared their invaluable insights and experiences with our glycemic management software. The discussion highlighted not only the positive impact on patient outcomes but also how the software has led to operational efficiencies and significant financial savings. If you’ve ever questioned whether investing in insulin dosing software is worth it, I encourage you to hear firsthand from these experts. Their stories provide clear evidence of how this technology can optimize care, enhance patient outcomes, and contribute to improved hospital performance, especially in light of the recent CMS announcement mandating the reporting of glycemic control measures.

Among our proudest accomplishments this year is the launch of our updated subcutaneous (SubQ) dosing solution. Although our customers appreciate the new, user-friendly interface, it is the immediate and material improvement in their hypo and hyperglycemia rates that has been the main reason for the enthusiasm we are seeing around this solution. Users are responding positively not only to the improved outcomes, but also to how it has revolutionized the way they approach insulin dosing across their hospitals. We are excited to continue supporting our existing customers and helping them leverage this enhanced tool to improve glycemic control and patient care.

As we look toward the future, I want to personally express my gratitude to our customers for their ongoing support and trust. Our team is deeply committed to providing the best customer experience in the industry, and we are honored to be a part of your journey toward better patient care. We look forward to continuing to serve you for many years to come.

On behalf of the entire team at Monarch, I wish you a joyful holiday season and a successful year ahead.